Certara prelims

 Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 million

Confirms Adjusted EBITDA within Guidance Range of $120 million to $124 million

Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced revenue and bookings for the fourth quarter and full year of fiscal year 2024 based on a preliminary review of fourth quarter results.

Preliminary financials for the fourth quarter of 2024 are expected to be as follows:

• Revenue of $99.7 million, compared to $88.0 million in the fourth quarter of 2023, representing growth of 13%.
  • Software revenue of $41.6 million, compared to $33.6 million in the fourth quarter of 2023, representing growth of 24%.
  • Services revenue of $58.1 million, compared to $54.4 million in the fourth quarter of 2023, representing growth of 7%.
• Bookings of $144.5 million, compared to $118.9 million in the fourth quarter of 2023, representing growth of 22%.
  • Software bookings of $59.7 million, compared to $43.3 million in the fourth quarter of 2023, representing growth of 38%.
  • Services bookings of $84.9 million, compared to $75.6 million in the fourth quarter of 2023, representing growth of 12%.
• Preliminary revenue and bookings include Chemaxon revenue of $5.9 million and bookings of $11.0 million. Certara completed the acquisition of Chemaxon on October 1, 2024.
  

Preliminary financials for the full year of 2024 are expected to be as follows:

• Revenue of $384.4 million, compared to $354.3 million in 2023, representing growth of 8%.
  • Software revenue of $155.0 million, compared to $131.7 million in 2023, representing growth of 18%.
  • Services revenue of $229.4 million, compared to $222.7 million in 2023, representing growth of 3%.1
• Bookings of $445.3 million, compared to $402.3 million in 2023, representing growth of 11%.
  • Software bookings of $169.4 million, compared to $136.9 million in 2023, representing growth of 24%.
  • Services bookings of $275.9 million, compared to $265.4 million in 2023, representing growth of 4%.

Certara also continues to expect adjusted EBITDA for the full year of 2024 between its previously disclosed guidance range of $120 million and $124 million.

https://www.globenewswire.com/news-release/2025/01/15/3009955/0/en/Certara-Reports-Preliminary-Fourth-Quarter-and-Full-Year-2024-Financial-Results.html